<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566501</url>
  </required_header>
  <id_info>
    <org_study_id>E2020-G000-328</org_study_id>
    <secondary_id>2006-004890-93</secondary_id>
    <nct_id>NCT00566501</nct_id>
  </id_info>
  <brief_title>Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease</brief_title>
  <official_title>Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of long-term administration
      of 23 mg donepezil sustained release (SR) in patients with moderate to severe Alzheimer's
      disease. Patients who complete study E2020-G000-326 with no ongoing serious adverse events
      (SAEs) and no serious adverse drug reactions will be eligible to enter the open-label
      extension study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term Safety as Measured by Incidence of Adverse Events During the 12 Month Treatment Period</measure>
    <time_frame>Throughout the study ( 12 months for all AEs and up to an additional 30 days for SAEs)</time_frame>
    <description>Adverse events (AEs), including SAEs, were recorded from the time of consent. Recording of AEs ceased after the Final Visit or Early Termination Visit, except that SAEs were monitored for 30 days after study drug discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in MMSE Score</measure>
    <time_frame>12 months</time_frame>
    <description>The Mini-Mental State Examination (MMSE) is a brief, 30-item test of cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SIB Score</measure>
    <time_frame>12 months</time_frame>
    <description>The Severe Impairment Battery (SIB) evaluates the severity of cognitive dysfunction in patients with more advanced dementia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">915</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>23 mg SR in Study 326</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg IR in Study 326</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>23 mg SR in Study 326</intervention_name>
    <description>Patients will receive 23 mg donepezil SR orally, once daily for 12 months.</description>
    <arm_group_label>23 mg SR in Study 326</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg IR in Study 326</intervention_name>
    <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
    <arm_group_label>10 mg IR in Study 326</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Patients:

          1. Written informed consent from the patient (if possible) or from the patient's legal
             guardian or other representative at the time of the Baseline visit, prior to beginning
             any assessments or activities.

          2. Completion of study E2020-G000-326 without ongoing SAEs or history of serious adverse
             drug reactions during study E2020-G000-326.

          3. Patients must enroll in the present study within 3 days of completion of study
             E2020-G000-326

          4. Health: physically healthy and ambulatory or ambulatory-aided (ie, walker or cane);
             corrected vision and hearing sufficient for compliance with testing procedures.

          5. Co-morbid medical conditions must be well-controlled as determined by the
             investigator.

          6. Patients undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) may
             be included provided that doses are within the approved dose range as specified in the
             Physician's Desk Reference or local equivalent

          7. Concomitant Medications: Patients undergoing treatment with the following medications
             may be enrolled in the study provided the following conditions are met: chronic daily
             benzodiazepine use if doses are stable within an approved dose range; bronchodilator
             medications for treatment of chronic obstructive pulmonary disease (COPD) as long as
             drug is administered via metered dose inhaler within approved dose range; memantine if
             taken at doses of 20 mg/day or less, provided that the dose is stable.

          8. The patient must have a relative/caregiver who supervises the regular taking of the
             drug at the correct dose and is alert for possible side effects, unless the patient's
             legal guardian takes on this task.

        Inclusion Criteria for Caregivers. Written informed consent will be obtained from the
        designated caregiver for participation in study assessments. The caregiver must be
        sufficiently familiar with the patient (as determined by the investigator) to provide
        accurate data. Specifically, the caregiver must have sufficient contact with the patient to
        provide accurate reports of the patient's functioning, must be able to observe for possible
        adverse events, and must be able to accompany the patient to all visits. It is preferable
        that the caregiver be the same as in study E2020-G000-326. If no replacement caregiver is
        available who meets the caregiver inclusion/exclusion criteria, the patient must be
        discontinued from the study.

        Exclusion Criteria for Patients:

          1. No caregiver available to meet the inclusion criteria for caregivers.

          2. Patients with any active or clinically-significant conditions affecting absorption,
             distribution, or metabolism of the study medication (e.g., inflammatory bowel disease,
             gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance).

          3. Known plan for elective surgery during the study period that would require general
             anesthesia and administration of neuromuscular blocking agents, such as
             succinylcholine, to induce paralysis/muscle relaxation. Minor surgery, such as
             colonoscopy or cataract surgery, will be permitted as long as it does not require the
             use of these paralytic agents.

          4. Patients who are unwilling or unable to fulfill the requirements of the study.

          5. Use of any prohibited prior or concomitant medications.

          6. Any condition that would make the patient, in the opinion of the investigator,
             unsuitable for the study.

          7. Patients taking concomitant antidepressant medication known to have significant
             anticholinergic effects, such as tricyclic antidepressants prescribed at doses
             recommended for the treatment of major depression.

          8. Patients who cannot swallow or who have difficulty swallowing whole tablets.

          9. Patients taking any alternative medication such as vitamins and/or herbal products or
             alternative medical techniques such as acupuncture or acupressure specifically for the
             treatment of Alzheimer's disease.

        Exclusion Criteria for Caregivers.

          1. Caregivers who are unwilling or unable to give informed consent or otherwise to
             fulfill the requirements of the study.

          2. Any condition that would make the caregiver, in the opinion of the investigator,
             unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>91 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Yardley, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Apex Research Institute</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <results_first_submitted>May 16, 2012</results_first_submitted>
  <results_first_submitted_qc>May 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2012</results_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate-to-severe</keyword>
  <keyword>Alzheimer's</keyword>
  <keyword>Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was recruited at 179 centers in Asia, Europe, North America, Oceania, South Africa, and South America during the period of 14 December 2007 to 01 April 2010.</recruitment_details>
      <pre_assignment_details>This study (E2020-G000-328) was a 12-month, open-label extension of study E2020-G000-326. Subjects who had received donepezil 10 mg IR or donepezil 23 mg IR during Study 326 were eligible for enrollment into this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>23 mg SR in Study 326</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
        </group>
        <group group_id="P2">
          <title>10 mg IR in Study 326</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="579"/>
                <participants group_id="P2" count="336"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="570"/>
                <participants group_id="P2" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdraw of Consent by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Request of Investigator or Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Medication Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Other ( Not Specified)</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Determined</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="423"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>23 mg SR in Study 326</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
        </group>
        <group group_id="B2">
          <title>10 mg IR in Study 326</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="579"/>
            <count group_id="B2" value="336"/>
            <count group_id="B3" value="915"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.1" spread="8.63"/>
                    <measurement group_id="B2" value="74.5" spread="8.46"/>
                    <measurement group_id="B3" value="74.2" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="435"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other ( not specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Long-term Safety as Measured by Incidence of Adverse Events During the 12 Month Treatment Period</title>
        <description>Adverse events (AEs), including SAEs, were recorded from the time of consent. Recording of AEs ceased after the Final Visit or Early Termination Visit, except that SAEs were monitored for 30 days after study drug discontinuation.</description>
        <time_frame>Throughout the study ( 12 months for all AEs and up to an additional 30 days for SAEs)</time_frame>
        <population>The Safety Population consisted of all subjects who received at least one dose of donepezil SR 23 mg during Study 328. Two groups were categorized: those who received donepezil 10 mg IR and those who received donepezil 23 mg SR during Study 326.</population>
        <group_list>
          <group group_id="O1">
            <title>23 mg SR in Study 326</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
          </group>
          <group group_id="O2">
            <title>10 mg IR in Study 326</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Safety as Measured by Incidence of Adverse Events During the 12 Month Treatment Period</title>
          <description>Adverse events (AEs), including SAEs, were recorded from the time of consent. Recording of AEs ceased after the Final Visit or Early Termination Visit, except that SAEs were monitored for 30 days after study drug discontinuation.</description>
          <population>The Safety Population consisted of all subjects who received at least one dose of donepezil SR 23 mg during Study 328. Two groups were categorized: those who received donepezil 10 mg IR and those who received donepezil 23 mg SR during Study 326.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="570"/>
                    <measurement group_id="O2" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in MMSE Score</title>
        <description>The Mini-Mental State Examination (MMSE) is a brief, 30-item test of cognitive function.</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SIB Score</title>
        <description>The Severe Impairment Battery (SIB) evaluates the severity of cognitive dysfunction in patients with more advanced dementia.</description>
        <time_frame>12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>23 mg SR in Study 326</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
        </group>
        <group group_id="E2">
          <title>10 mg IR in Study 326</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardio-rspiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Meningocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Peritonillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Device lead damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimers type</sub_title>
                <counts group_id="E1" events="570" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ischemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Poriomania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="415" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="259" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Satlin, Senior Vice President, Neuroscience Product Creation Unit</name_or_title>
      <organization>Eisai, Inc.</organization>
      <phone>201-949-4597</phone>
      <email>Andrew_Satlin@eisai.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

